# Clinical Cancer Research

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/clinical-cancer-research/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,646,710 |
| h-index | 421 |
| Homepage | http://clincancerres.aacrjournals.org/ |
| Open Access | false |
| ISSN-L | 1078-0432 |
| ISSNs | 1078-0432,1557-3265 |
| OpenAlex ID | https://openalex.org/S183149254 |
| Publisher | American Association for Cancer Research |
| Works | 27,687 |

## Journal papers

Showing 12 of 231.

- [Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma](https://scholariq.org/papers/immunohistochemical-and-clinical-characterization-of-the-basal-like-subtype-of/)
- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy](https://scholariq.org/papers/durable-complete-responses-in-heavily-pretreated-patients-with-metastatic/)
- [The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes](https://scholariq.org/papers/the-triple-negative-paradox-primary-tumor-chemosensitivity-of-breast-cancer/)
- [<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)
- [An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance](https://scholariq.org/papers/an-epithelial-mesenchymal-transition-gene-signature-predicts-resistance-to-egfr/)
- [Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment](https://scholariq.org/papers/sarcopenia-as-a-determinant-of-chemotherapy-toxicity-and-time-to-tumor/)
- [Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma](https://scholariq.org/papers/potential-predictive-value-of-i-tp53-i-and-i-kras-i-mutation-status-for-response/)
- [Circulating Tumor Cells in Patients with Breast Cancer Dormancy](https://scholariq.org/papers/circulating-tumor-cells-in-patients-with-breast-cancer-dormancy/)
- [A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response](https://scholariq.org/papers/a-pilot-trial-using-lymphocytes-genetically-engineered-with-an-ny-eso-1-reactive/)
- [Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies](https://scholariq.org/papers/phase-i-and-pharmacokinetic-study-of-genexol-pm-a-cremophor-free-polymeric/)
- [Clinical Trial Substantiates the Predictive Value of <b> <i>O-6-Methylguanine-DNA Methyltransferase</i> </b> Promoter Methylation in Glioblastoma Patients Treated with Temozolomide](https://scholariq.org/papers/clinical-trial-substantiates-the-predictive-value-of-b-i-o-6-methylguanine-dna/)

## Journal top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Cells and Metastasis](https://scholariq.org/topics/cancer-cells-and-metastasis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.